Recommended

Discover how to overcome low affinity or poor TCR yields that are slowing you down in this upcoming webinar – register your details today
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk – register your details now
Unlock the science, strategy and real-world impact behind the next generation of precision therapies – access our new brand report now >>
Safety data is no longer just a regulatory checkbox – it’s a strategic advantage. Find out more in our upcoming webinar, register your details today
Explore how AI is reshaping early drug discovery, from target identification and compound screening to predictive modelling and trial design – register now!
article

Expert view: Where are you seeing changes in the flow cytometry market?

Posted: 10 September 2020 | | No comments yet

We have entered a new era of drug discovery where the use of advanced cell models such as multi-cellular co-cultures, stem cells and CRISPR-based screens can lead to the next generation of therapeutics.

As an example, in the field of oncology, the focus has shifted to a novel class of biologics and cell therapies that modulate immune cell function. This change in therapeutic approach and model complexity requires tools that assess multiple cell parameters to better understand the cellular mechanisms or synergistic effects of combinatorial drug treatments earlier in the discovery process. Furthermore, severe constraints on essential primary cells drive the desire to miniaturise assays and compress analysis workflows.

Flow cytometry is a powerful, widespread and flexible technology that delivers high-content information from single cells and particles. However, the limited throughput, slow sampling speeds and large sample volume requirements of traditional flow cytometry technologies present barriers for the drug discovery industry. As such, flow cytometry technologies need to deliver  high-throughput content in a miniaturised format and to analyse and visualise the large datasets generated during drug development studies.

 

Reserve your FREE place

 


Are low affinity or poor TCR yields slowing you down?

Explore how CHO expression of soluble TCRs and TCR affinity maturation workflows via phage, serving as essential building blocks for early-stage TCR-TCE candidate generation.

22 October 2025 | 16:00 PM BST | FREE Webinar

Join Jiansheng Wu, Ph.D. to explore two integrated strategies:

  • High-titer CHO-based expression of sTCRs (~100 mg/L), enabling scalable and high-throughput production
  • Optimized phage display affinity maturation, improving TCR binding by up to ~10,000-fold

Whether you’re starting a new TCR program or optimizing an existing platform, this session will offer actionable strategies to accelerate discovery and improve candidate quality.

Register Now – It’s Free!

 

The iQue® 3 advanced flow cytometry platform from Sartorius, for example, is purpose built for rapid microplate sampling and plate-based data management. This automation-friendly platform performs high-throughput, miniaturised assays assessing immuno-phenotyping, cell health, killing potential and bead-based cytokine profiling in a single well of a 96- or 384-well microtiter plate. The integrated iQue® Forecyt® software delivers real-time, plate-based data analysis and visualisation of results providing actionable answers in minutes per plate, not hours or days.

As the market trends towards more complex and physiologically relevant cell-based assays for drug discovery, the advancement of technologies and tools that analyse large numbers of samples and complex datasets is critical for the development of the next generation of therapies.